- Report
- April 2025
- 193 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- May 2024
- 136 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- January 2025
- 120 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- January 2025
- 150 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- April 2025
- 179 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 372 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- August 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- May 2024
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
- 100 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- August 2023
- 285 Pages
Global
From €4505EUR$4,950USD£3,827GBP
- Report
- August 2024
- 80 Pages
Japan
From €3186EUR$3,500USD£2,706GBP
- Report
- February 2024
- 113 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- April 2023
- 111 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2022
- 116 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4505EUR$4,950USD£3,827GBP
- Report
- April 2021
- 101 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- November 2023
- 47 Pages
Global
From €3636EUR$3,995USD£3,088GBP
- Report
- May 2023
- 2488 Pages
Global
From €2275EUR$2,500USD£1,933GBP

Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of hematological malignancy, which is a cancer of the blood or bone marrow. Myeloma is the second most common type of hematological malignancy, after lymphoma. Symptoms of myeloma include bone pain, anemia, frequent infections, and kidney problems. Treatment options include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.
The myeloma market is a subset of the hematology market, which is a large and growing market. The market is driven by the increasing prevalence of hematological malignancies, as well as advances in treatment options. The market is expected to continue to grow in the coming years, as new treatments are developed and more patients are diagnosed.
Some companies in the myeloma market include Bristol-Myers Squibb, Celgene, Novartis, and Takeda. Show Less Read more